Coming to Grips with Chronic Heart Failure: Keeping Up with Best Practices
January 23, 2020
January 23, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Boston University School of Medicine and Rockpointe.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other health care professionals completing this course will be issued a statement of participation.
The intended audiences for this initiative include community cardiologists, internists, hospitalists, and other healthcare professionals involved in the management of patients with heart failure.
Heart failure (HF) affects nearly 6 million people in the United States. Advances in the understanding of the pathophysiology of HF have led to the development of several classes of effective HF treatments, including two recently approved agents. Despite the availability of many agents with varying mechanisms of action, patients are often not managed in an evidence-based fashion and the 5-year mortality rate for HF remains high, at approximately 50%.
This CME activity, “Coming to Grips with Chronic Heart Failure: Keeping Up with Best Practices,” will review the current understanding of the pathophysiology of HF (including HF with reduced ejection fraction and HF with preserved ejection fraction), describe the currently available agents for the management of HF and their evidence-based roles in treating patients, and discuss the role of the interdisciplinary healthcare team in the development of comprehensive patient-care strategies.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care, practicing evidence-based medicine.
Upon completion of this activity, participants should be able to:
- Identify the major drivers of HF and develop treatment strategies to counter them
- Empower interdisciplinary healthcare teams to implement comprehensive patient-care strategies
- Develop management strategies that include use of newer therapies in those HF patients who stand to benefit
Javed Butler, MD, MPH, MBA
Professor and Chairman
Department of Medicine
University of Mississippi
Muthiah Vaduganathan, MD, MPH
Instructor of Medicine, Harvard Medical School
Center for Advanced Heart Disease
Brigham and Women's Hospital
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Javed Butler, MD, MPH, MBA
- Consultant: Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, Vifor
Muthiah Vaduganathan, MD, MPH
- Consultant: Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim
Michael Klein, MD, BUSM Course Director: Nothing to disclose.
Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry Ann Glauser, MD, MPH; Blair St. Amand; Natalie Sanfratello, MPH; Elizabeth Drury: Nothing to disclose.
Disclosure of Unlabeled Use
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
There is no fee for this educational activity. In order to receive credit, you must watch the webcast, pass the posttest with a score of 75% or greater, and complete the evaluation. You will have multiple opportunities to take and pass the posttest.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.